Videos
CARTITUDE-2 Cohort B: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and Early Relapse After Initial Therapy
What is the purpose of this trial?
CARTITUDE-2 is a phase 2, multicohort study evaluating the efficacy…
Videos
Matching-Adjusted Indirect Comparison Study: Health-related Quality of Life in RRMM Patients Treated with Ide-Cel vs Belantamab Mafodotin Presented at EHA 2022
Dr.Nina Shah Discusses Health-related Quality of Life in RRMM Patients Treated with Idecabtagene Vicleucel (Ide-Cel) vs Belantamab…
Videos
Interim Phase 1b Study Results on Isatuximab and Pd Subcutaneous Administration in RRMM Patients Presented at ASCO 2022
Abstract Title:
Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with…
Videos
Updates on Phase 1b TRIMM-2 Study Results of Teclistamab + Daratumumab Presented at EHA 2022
Dr. Paula Rodríguez-Otero Provides Updates on Phase 1b TRIMM-2 Study Results of Teclistamab + Daratumumab in RRMM Patients
Abstract Title:
Teclistamab in Combination with Daratumumab, a Novel,…
Videos
Updated Efficacy/Safety Results of MajesTEC-1 (Teclistamab) at ASCO 2022
Dr. Ajay Nooka Discusses Updated Efficacy/Safety Results of MajesTEC-1 (Teclistamab) in RRMM Patients
Abstract Title:
Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with…
Videos
Updates on the Phase 3 DETERMINATION Trial Presented at ASCO 2022
Dr. Paul G. Richardson Provides Study Updates on the Phase 3 DETERMINATION Trial for Newly Diagnosed Multiple Myeloma Patients
Abstract title:
Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell…
Videos
Efficacy and Safety of ARI0002H (BCMA-Directed CAR T) in RRMM Patients Presented at EHA 2022
Dr. Carlos Fernandez de Larrea Discusses Efficacy and Safety of BCMA-Directed CAR T-Cell Therapy (ARI0002H) in RRMM Patients
Abstract Title:
Efficacy and Safety of ARI0002H, an Academic BCMA-…
Videos
Initial Safety Results for Phase 2 MagnetisMM-3 Trial Presented at ASCO 2022
Dr. Alexander M. Lesokhin Discusses Initial Safety Results for MagnetisMM-3: Phase 2 Trial of Elranatamab (BCMA)-CD3 Bispecific Antibody in RRMM Patients
Abstract Title:
Initial safety results…
Videos
Phase 1 Study of CAR T-ddBCMA in RRMM Presented at ASCO 2022
Dr. Matthew J. Frigault Discusses the Phase 1 Study of CAR T-ddBCMA in RRMM Patients
In this video:
Dr. Matthew J. Frigault (Harvard Medical School, Massachusetts General Hospital—Boston, MA)…
Audio
A Day in the Life: Terrence and Toni Green's Myeloma Journey
You're listening to A Day in the Life Podcast, brought to you by the International Myeloma Foundation. We hope this podcast provides messages of hope and resilience for those in the myeloma community and beyond. Today we're talking to…
News Article
LOS ANGELES, CA, JUNE 8, 2022—The International Myeloma Foundation (IMF) is proud to announce the recipients of this year's Robert A. Kyle Achievement Award and Brian G.M. Durie Outstanding Achievement Award, which will be presented in an in-person awards ceremony today, June 8th,…
Videos
Should patients start bone therapy while in remission?
Myeloma expert Dr. Brian G.M. Durie discusses if patients should start bone therapy while in remission.
The BOTTOM LINE: Talk to your doctor about your situation. Myeloma patients who are in deep…
Videos
Brand-name drugs versus generic treatment options
Multiple myeloma expert Dr. Brian G.M. Durie discusses if patients should consider switching from brand-name drugs to available generic options.
The BOTTOM LINE: Talk to your doctor to see if there is any benefit…
Videos
Virtual Multiple Myeloma Community Workshop A virtual multiple myeloma workshop addressing the needs specific to communities in the Midwest Region of the United States.The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis,…
Event
My name is George, and I lost my dad and a brother to multiple myeloma. My wife, Julia's best friend, is on her 11th year fighting this dreadful disease. So, this year as Julia and I celebrate our 50th anniversary, we decided to help by collaborating with the International Myeloma…
Videos
What Should Myeloma Patients Know About CAR T-Cell Therapy?
Myeloma expert Dr. Brian G.M. Durie answers the question: What is CAR T-cell therapy and what patient population is this immunotherapy currently approved for?
The BOTTOM LINE: CAR T-cell therapy is…
Page
国际骨髓瘤基金会 (IMF) 成立于 1990 年，是第一个也是最大的专注于多发性骨髓瘤的组织。基金组织的影响力扩展到全球 140 个国家的 525,000 多名成员。 IMF 致力于提高骨髓瘤患者的生活质量，同时通过我们的四项创始原则：研究、教育、支持和宣传，致力于预防和治疗。
国际货币基金组织为患者和护理人员以及医疗保健专业人员制作并维护着一个包含最新教育出版物和期刊的广泛图书馆。基金组织的所有出版物始终免费，可通过单击下面的链接下载。
出版物…
Videos
What Patients and Caregivers Need to Know About the Newest in Myeloma Care, Side Effect Management, and CAR T-cell Therapies
The IMF Patient and Family Webinar focuses on “New Frontiers in Myeloma Care.” IMF Chairman Dr. Brian G.M. Durie moderated presentations with the following myeloma experts…
Videos
The Ongoing COVID-19 Pandemic and Myeloma Patient Safety
Myeloma expert Dr. Brian G.M. Durie discusses the ongoing pandemic, emerging variants of concern, and how myeloma patients should continue preventative measures to stay safe.
The BOTTOM LINE: The COVID-19…
News Article
LOS ANGELES, CA, MAY 12, 2022—The International Myeloma Foundation (IMF) announced today that Fatima Scipione, former Head of Global Oncology Patient Advocacy and Engagement at Takeda Oncology, has been named by the nonprofit research and patient advocacy organization as its new…
News Article
Members of the myeloma community fund important myeloma research
By Suzanne Battaglia
IMF Senior Director, Member Events
Since 1994, the IMF has funded more than 150 of the most promising myeloma research projects by talented investigators from leading institutions around the world. The IMF’…
News Article
YOU can help the IMF collect and study important data to ensure that the right patient gets the right treatment at the right time!
By Lynn K. Green, Ed.D.
IMF Senior Vice President, Philanthropy
Patients have always been the primary focus of the IMF’s mission: to improve the quality of life…
Videos
Virtual Multiple Myeloma Community Workshop A virtual multiple myeloma workshop addressing the needs specific to communities in the Mountain Region of the United States.The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis,…
News Article
5th Annual AMN Summit, Inaugural Master Class for Doctors, and Patient Forum
By Daniel Navid
IMF Senior Vice President, Global Affairs
The IMF Asian Myeloma Network held three groundbreaking events for the region, which took place on consecutive weekends in October 2021.…
News Article
Patients must have access to oral cancer therapies
By Robin Levy
IMF Senior Director, Public Policy & Advocacy
Improving access to lifesaving medications for myeloma patients is a long-standing commitment of the International Myeloma Foundation (IMF).
For many years, the IMF Advocacy…
Videos
New Immune Therapies for Myeloma Patients
In this week's episode, myeloma expert Dr. Brian G.M. Durie discusses what myeloma patients should know about the three types of immune therapies: Cellular therapies, antibody-drug conjugates (ADC), and bispecific antibodies.
The BOTTOM LINE…
Audio
You're listening to A Day in The Life podcast brought to you by the International Myeloma Foundation. We hope this podcast provides messages of hope and resilience for those in the myeloma community and beyond.
Today, we are talking to Thomas Goode, who was diagnosed with myeloma in 2005, at the…
Event
In 2007, I was diagnosed with multiple myeloma. At that time, there was only a few drugs approved and those were very taxing on you. Revlimid had just been approved so I started with Revlimid, velcade and dexamethazone (RVD). RVD worked great at first, but within 6 months the myeloma came…
Videos
What is the IMF's virtual tissue bank?
Myeloma expert Dr. Brian G.M. Durie discusses the virtual biobank being developed by the International Myeloma Working Group (IMWG).
The BOTTOM LINE: The virtual tissue bank is a major development that will enhance collaborative research…
News Article
STUDIO CITY, CA, April 6, 2022 — As this year’s Myeloma Action Month came to a close, the International Myeloma Foundation (IMF) was unwavering in achieving its goals. By encouraging individuals and groups to take action for myeloma through a powerful social media campaign, the IMF…
Videos
Virtual Multiple Myeloma Community Workshop A virtual multiple myeloma workshop addressing the needs specific to communities in the West South Central Region of the United States.The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at…
Audio
This "A Day in the Life" podcast provides messages of hope and resilience to those in the myeloma community and beyond. In this episode we're talking to Marisel Brignoni from San Juan, Puerto Rico. Marisel is a FEMA disaster relief specialist who's working on the disaster relief for Hurricane…
Page
The Role of Oncology Nurses and Advanced Practitioners in Advancing Health Equity in the Field of Multiple Myeloma
The following videos, presented by Medscape Oncology, are designed for healthcare practitioners to earn certified medical education (CME) credits.
In this CME series, …
Page
Understanding the Language of Multiple Myeloma
Myeloma is a complicated disease, but the language that describes myeloma doesn’t have to be hard to understand. To play an active role in your own medical care, it is helpful to learn the myeloma-related terms that may be used in your discussions…
Videos
Virtual Multiple Myeloma Community Workshop A virtual multiple myeloma workshop addressing the needs specific to communities in the Northeast Tri-State of the United States.The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis,…
Event
Single Malt Scottish Whisky Tasting Tour in the comfort of your own home or venue of your choosing.
Videos
What Patients and Caregivers Need to Know About Side Effect Management and Living Well with Myeloma
DOWNLOAD SLIDES
Speakers
Agenda…
Page
Our hearts go to all innocent victims of the ongoing conflict in Ukraine.
As a global organization, the International Myeloma Foundation supports — and will continue to support — every myeloma patient, caregiver, doctor, researcher, and advocate going through struggles and difficulties…
Page
What Is Carvykti?
CARVYKTI® (also known as ciltacabtagene autoleucel, the generic drug name) or “cilta-cel” for short. Carvykti was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM).…
News Article
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of…
Event
A virtual multiple myeloma workshop addressing the needs specific to communities in the Northeast Tri-State of the United States.
Register Now
Videos
IMF Patient and Family Webinar
Learn how to better manage side effects, discover optimal choices for relapsed patients, receive updates on ASH 2021 and 2022 COVID-19 Guidance, gather information about CAR T-cell therapies, and more. IMF Chairman of the Board Dr. Brian G.M. Durie moderates…
News Article
STUDIO CITY, Calif., Feb. 25, 2022 — With the International Myeloma Foundation (IMF) at the forefront, Myeloma Action Month is held every year for the whole month of March to encourage individuals and groups to take actions that positively impact the myeloma community. This year,…
Videos
What Is Mass Spectrometry?
Myeloma expert Dr. Brian G.M. Durie discusses mass spectrometry and how it can benefit myeloma patients.
The BOTTOM LINE: Mass spectrometry is a very accurate testing method that measures the level of myeloma protein in blood and urine.…
Videos
Multiple Myeloma Patients Experiencing Bone Disease
Multiple myeloma expert Dr. Brian G.M. Durie discusses the treatment options available to myeloma patients experiencing bone disease and if there is a new standard of care for treatment of the disease.
The BOTTOM LINE:…
Videos
Paxlovid Has Been Granted Emergency Use Authorization To Treat the COVID-19 Infection.
Myeloma Expert Dr. Brian G.M. Durie answers the question: How does Pfizer’s antiviral pill used to treat COVID-19 infections benefit myeloma patients?
The BOTTOM LINE: Paxlovid™…